Neurocrine Biosciences Inc vs United States Natural Gas Fund — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while United States Natural Gas Fund trades at $10.45. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| NBIX | UNG | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | Commodities - Energy |
52-Week High | $180.55 | $16.90 |
52-Week Low | $123.10 | $10.15 |
Enterprise Value | $16.49B | — |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
UNG trades at $10.29, down 2.09% today, with a bearish technical signal driven by moving averages. The ETF tracks natural gas futures, facing volatility from weather and LNG demand shifts. Recent news highlights comparisons with equity-based natural gas ETFs like FCG, emphasizing UNG's direct exposure to Henry Hub spot prices.
Outlook remains tied to natural gas market dynamics, with risks from storage reports and production levels. Investment appeal hinges on commodity price speculation, but high volatility and lack of traditional fundamentals limit suitability for conservative investors.
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →